KALA News and Press, Kala Pharmaceuticals Inc. From 04/24/21

Kala Pharmaceuticals has had a torrid time growing sales of its first approved ocular therapy Inveltys, for postoperative pain, which earned just $6.1m in FY20. In October last year, Kala won approval for Eysuvis, a corticosteroid treatment for short-term symptoms of dry eye disease -...

The following slide deck was published by Kala Pharmaceuticals, Inc. in conjunction with this event. For further details see: Kala Pharmaceuticals (KALA) Presents At Oppenheimer 31st Annual Healthcare Conference - Slideshow

-- Commercial formulary coverage effective May 15, 2021 -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that Cigna has added ...

Start Time: 08:00 End Time: 08:48 Kala Pharmaceuticals, Inc. (KALA) Q4 2020 Earnings Conference Call February 25, 2021, 08:00 AM ET Company Participants Mark Iwicki - Chairman, President and CEO Mary Reumuth - CFO Todd Bazemore - COO Kim Brazzell - Chief Medical Officer Hongming Chen - Chief ...

Kala Pharmaceuticals (KALA): Q4 GAAP EPS of -$0.55 misses by $0.09.Revenue of $2.24M (+89.8% Y/Y) misses by $0.15M.Shares +2.4% PM.Press Release For further details see: Kala Pharmaceuticals EPS misses by $0.09, misses on revenue

-- Launched EYSUVIS™, First and Only Prescription Therapy Approved Specifically for Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease -- -- Progressing Pipeline Programs to Address Front and Back of Eye Diseases -- -- Cash Position and INVELTYS R...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report fourth quarter and full year 2020 financial results on Thursday, Februar...

Express Scripts coverage effective February 5, 2021 Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that Express Scripts, one o...

Kala Pharmaceuticals’ Eysuvis, a corticosteroid-based drug, was approved for treating both signs and symptoms of dry eye disease last year and launched in Jan 2021. Eysuvis’ unique treatment target - dry eye flare - makes it a complementary therapy, rather than a direct ...

-- First and only prescription therapy approved specifically for short-term treatment of the signs and symptoms of dry eye disease now available in pharmacies nationwide -- -- Advancing multiple NCE development programs targeted to address front and back of eye diseases ...